Advanced non-small cell lung cancer with malignant pleural e
Conditions
Interventions
A:High-dose endovascular perfusion
B:Conventional dose of endovascular perfusion
C:platinum intracavitary
Sponsors
First Affilicated Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The histological and / or cytological diagnosis of advanced non-squamous, non-small cell lung cancer; 2. According to the latest stage of IASLC 2009 lung cancer TNM, it is determined as advanced non-small cell lung cancer; 3. Combined with moderate to upper malignant pleural effusion, and ECOG PS: 0-2 minutes; 4. The expected survival =3 months; blood tests: ANC =2×10^9/L and PLT =100×10^9/L and HB=9g/dL; 5. biochemical tests must meet the following criteria: BIL <1.25 times the upper limit of normal (ULN); ALT and AST <2.5 × ULN; if liver metastases, the ALT and AST <5 × ULN; Serum Cr=1 × ULN, creatinine clearance rate =50ml/min (Cockcroft-Gault formula); 6. The electrocardiogram is basically normal, and there is no unhealed wound on the body; 7. Patients who have undergone surgery have been more than 4 weeks since the start of the study and the patient has recovered; 8. Previously no serious allergic reactions to biological agents, especially E. coli genetic engineering products; 9. The patient voluntarily informed consent (ICF).
Exclusion criteria
Exclusion criteria: 1. Benign disease with pleural effusion; 2. A pregnant or lactating women, or female patients who have fertility but have not used contraception; 3. There are serious acute infections that are not controlled,or a suppurative and chronic infection with a prolonged wound; 4. People with serious heart disease, including congestive heart failure, uncontrolled high-risk arrhythmia, unstable angina, myocardial infarction, severe heart valve disease, and refractory hypertension; 5. The patient has an uncontrollable neurological, psychiatric or psychiatric disorder with poor compliance and cannot be treated with treatment;The transfer of the central nervous system with symptoms; 6. Having bleeding tendencies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| TTP;QOL;ECOG;The rate of advers reactions; | — |
Countries
China
Contacts
Public ContactJia Yingjie
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed